AOD9604 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-04-23 and is reviewed periodically as new material appears.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
At first glance, this result would seem to contradict the assertion that states choose alliance partners in order to balance against the strongest. Focusing solely on aggregate power would lead us to expect more states to ally with the Soviet Union, in order to prevent the United States from using its superior overall resources in harmful ways. Judging from the preponderance of aggregate power favoring the West, many states appear to have 'bandwagoned' rather than balanced by aligning with the United States. This is even more striking when one remembers that the United States was overwhelmingly the world's most powerful country in the immediate postwar period, yet was able to bring most of the other industrial powers into alignment with rather than against it. In 1986, still not envisaging the end of the Cold War in sight, Zbigniew Brzezinski emphasized the historical uniqueness of the current period regarding the preponderance of power: "[N]ever before would the eclipse of one of the major rival powers have given to the other effective global preponderance." Shortly after one of the rival superpowers eclipsed, the Pentagon Regional Defense Strategy (1992) formulized: "It is not in our interest … to return to earlier periods in which multiple military powers balanced one against another in what passed for security structures, while regional or even global peace hang in the balance." In the first post-Cold War year, Leffler advocated for the United States to continue its strategy of "preponderance of power".
=== Other vaccines === In May 2024, Moderna's mResvia, an mRNA respiratory syncytial virus vaccine, was authorized for medical use in the United States. The company's mCombriax, a combined messenger RNA vaccine for protection against influenza and COVID‑19 was authorized for marketing in the European Union in February 2026. Their influenza vaccine, mFlusiva (mRNA-1010), was approved for medical use in the United States in August 2026 for people over the age of 50.
The median age of menarche for a population may be an index of the proportion of undernourished females in the population, and the width of the spread may reflect unevenness of wealth and food distribution in a population. Researchers have identified an earlier age of the onset of puberty. However, they have based their conclusions on a comparison of data from 1999 with data from 1969. In the earlier example, the sample population was based on a small sample of white females (200, from Britain). The later study identified as puberty as occurring in 48% of African-American females by age nine, and 12% of white females by that age. One possible cause of a delay in the onset of puberty past the age 14 in females and 15 in males is Kallmann syndrome, a form of hypogonadotropic hypogonadism (HH). Kallmann syndrome is also associated with a lack of sense of smell (anosmia). Kallmann syndrome and other forms of HH affect both men and women. It is caused by a failure in HPG axis at puberty which results in low or zero gonadotropin (LH and FSH) levels with the subsequent result of a failure to commence or complete puberty, secondary hypogonadism and infertility.
== History == From 1946 to 1948, the eleven states formed a single British crown colony known as the Malayan Union. Due to opposition from Malay nationalists, the Union was disbanded and replaced by the Federation of Malaya, which restored the symbolic positions of the rulers of the Malay states and introduced greater restrictions on the attainment of citizenship status. Within the Federation, while the Malay states were protectorates of the United Kingdom, Penang and Malacca remained British colonial territories. Like the Malayan Union before it, the Federation did not include Singapore, despite its traditional connections with Malaya. The Malaya Agreement was formulated by the British–Malay Pleno Conference between June and December 1946. At the end of the meeting, the Pleno Conference produced a 100-page "Blue Book." It was signed on 21 January 1948 at King House by the Malay rulers, and by Sir Edward Gent as the representative of the British government. The Agreement superseded the Agreement creating the Malayan Union, and prepared for the establishment of the Federation of Malaya on 1 February 1948. The position of the Malay rulers was also restored. The Federation became independent from British colonial rule and became an independent member of the Commonwealth of Nations on 31 August 1957. In 1963, the Federation was reconstituted as "Malaysia" when it federated with the British territories of Singapore, Sarawak, and North Borneo; a claim to the latter territory was maintained by the Philippines.
Sources: en.wikipedia.org
== Commentary == In December 2014, an exhibition by Carmen Weisskopf and Domagoj Smoljo entitled "The Darknet: From Memes to Onionland" explored Darknet culture. This featured a bot called the "Random Darknet Shopper" which spent $100 in BTC per week on products listed on Agora. Their aim was to explore the ethical and philosophical implications of these markets, which, despite high-profile internationally co-ordinated raids, persist and flourish. James Martin's 2014 book Drugs on the Dark Net: How Cryptomarkets are Transforming the Global Trade in Illicit Drugs discusses some vendors who are even branding their opium or cocaine as "fair trade", "organic" or sourced from conflict-free zones. In June 2015 journalist Jamie Bartlett gave a TED talk about the state of the darknet market ecosystem as it stood at the time. According to 2014 studies by Martin Aldridge & Décary-Hétu and a January 2015 report from the Global Drug Policy Observatory, many harm reduction trends have been spotted. These include the reduced risks associated with street dealing such as being offered hard drugs. The vendor feedback system provides accountability for risks of mixing and side effects and protection against scammers. Online forum communities provide information about safe drug use in an environment where users can anonymously ask questions. Some users report the online element having a moderating effect on their consumption due to the increased lead time ordering from the sites compared to street dealing.
=== Industrial radiography === During World War II, Van de Graaff had used the compact generator invented with Trump to detect defects in ship hulls and ordnance for the U.S. Navy. Drawing on this application, HVEC produced 2-MeV industrial X-ray generators for non-destructive testing of manufactured goods. These units, capable of detecting flaws in thick steel sections, weighed more than two tons and were designed to operate in industrial facilities. HVEC adapted these generators to output electron beams, selling a line of industrial radiography equipment and also renting sterilization services to other companies. In 1957, Ethicon, a medical subsidiary of Johnson & Johnson, purchased an HVEC linear accelerator to sterilize surgical sutures, the first commercial medial product to use radiation processing. Sales of e-beam processing machines picked up after HVEC introduced insulating core transformers. ICTs, operating in the lower-voltage 300 keV to 2.5 MeV range, were used for crosslinking polyethylene and other polymers. W. R. Grace's Cryovac division used radiation crosslinking to produce heat-shrinkable materials for food packaging. Other companies purchased ICTs for extended to wire and cable insulation, rubber vulcanization, auto paint, textile modification, and semiconductors.
=== Fatality === A systematic meta analysis showed that cannabis users double the chance of dying from heart disease. Cannabis users had a 29% higher risk of heart attack and a 20% higher risk of stroke than non-users. There is an association between cannabis use and suicide, particularly in younger users. A 16-month survey of Oregon and Alaska emergency departments found a report of the death of an adult who had been admitted for acute cannabis toxicity. A recent study in 2025 suggests that individuals diagnosed with cannabis use disorder—characterized by an inability to stop using cannabis despite its negative effects—face a nearly threefold increase in mortality rates compared to those without the condition over a five-year period. The research indicates that people with this disorder are ten times more likely to die by suicide than the general population. Additionally, they have a higher risk of death from trauma, drug poisoning, and lung cancer. In a separate study researchers found an increase in schizophrenia and psychosis cases in Canada linked to cannabis use disorder following the drug's legalization.
Sources: en.wikipedia.org
== Air Force career == John Chain had a wide and varied military career, serving in a number of powerful positions. He accrued over 5,000 flying hours (including 400 combat hours) in more than 45 different military aircraft. He is a master parachutist with 66 jumps, and has been awarded the Air Force Distinguished Service Medal, the Legion of Merit, the Distinguished Flying Cross, and the Bronze Star. Chain was commissioned as a second lieutenant through the Air Force Reserve Officer Training Corps program. He received his pilot wings in 1957 and then entered combat crew training. From 1958 to 1959 the general was an F-100 Super Sabre pilot at Toul-Rosières Air Base in France, and from 1959 to 1962 at Ramstein Air Base in West Germany. General Chain then served as a flight examiner at Cannon Air Force Base, New Mexico. In 1964 he was assigned as a forward air controller in Fort Campbell, Kentucky. While there he became a master parachutist and flew Army O-1s and Air National Guard F-84 Thunderjets. In 1966 Chain flew combat missions while assigned to Tan Son Nhut Air Base in South Vietnam. He then transferred to Washington, D.C. From 1969 to 1970, Chain was an exchange officer with the U.S. Department of State. He entered the National War College in 1970 and upon graduation was assigned to Davis-Monthan Air Force Base in Arizona as deputy commander for operations. In 1972 he became deputy commander for logistics. In 1972 and 1973, Chain flew combat missions in F-4 Phantoms from Korat Royal Thai Air Force Base in Thailand.
Reactions of acids are often generalized in the form HA ⇌ H+ + A−, where HA represents the acid and A− is the conjugate base. This reaction is referred to as protolysis. The protonated form (HA) of an acid is also sometimes referred to as the free acid. Acid–base conjugate pairs differ by one proton, and can be interconverted by the addition or removal of a proton (protonation and deprotonation, respectively). The acid can be the charged species and the conjugate base can be neutral in which case the generalized reaction scheme could be written as HA+ ⇌ H+ + A. In solution there exists an equilibrium between the acid and its conjugate base. The equilibrium constant K is an expression of the equilibrium concentrations of the molecules or the ions in solution. Brackets indicate concentration, such that [H2O] means the concentration of H2O. The acid dissociation constant Ka is generally used in the context of acid–base reactions. The numerical value of Ka is equal to the product (multiplication) of the concentrations of the products divided by the concentration of the reactants, where the reactant is the acid (HA) and the products are the conjugate base and H+.
Depending on the chemistry, they may settle within the reactor core or travel through the coolant system and chemistry control systems are provided to remove them. In a well-designed power reactor running under normal conditions, coolant radioactivity is very low. The isotope responsible for most of the gamma exposure in fuel reprocessing plants (and the Chernobyl site in 2005) is caesium-137. Iodine-129 is a major radioactive isotope released from reprocessing plants. In nuclear reactors both caesium-137 and strontium-90 are found in locations away from the fuel because they're formed by the beta decay of noble gases (xenon-137, with a 3.8-minute half-life, and krypton-90, with a 32-second half-life) which enable them to be deposited away from the fuel, e.g. on control rods.
=== Military lull (August) === Active hostilities slowed in August 2026, when the formal 60-day deadline set by the June MoU officially expired. The Strait of Hormuz remained disrupted during this period and mediators Oman and Qatar were involved in backdoor diplomacy, slowing world energy shipping to a fraction of its pre-war volume.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.